Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

Published
16 September 2014
From
NATAP
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

An analysis of people who experienced treatment failure on their first-line HIV therapy with a viral load of over 400 copies/ml and who had taken either

Published
09 September 2014
By
Gus Cairns
Switching from first-line ART with suppressed viral load linked to treatment failure

People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported

Published
29 July 2014
By
Liz Highleyman
Dolutegravir demonstrates good efficacy despite resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who had virus with resistance to

Published
24 July 2014
By
Liz Highleyman
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients

The majority of people taking antiretroviral therapy (ART) that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen

Published
11 July 2014
By
Michael Carter
Switch from single-tablet regimen to 3 tablets works in Denmark

Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

Published
10 July 2014
From
International AIDS Society
New ARV prescribing guidelines for London (2014)

The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

Published
01 July 2014
From
HIV i-Base
People starting therapy on a boosted protease inhibitor don't need to switch after one virological failure episode, study indicates

Remaining on the same regimen is a “reasonable” strategy for people taking first-line antiretroviral therapy (ART) based on a ritonavir-boosted protease inhibitor who experience virologic failure, according to

Published
09 June 2014
By
Michael Carter
Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

Published
10 March 2014
From
HIV i-Base
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
← First12345...23Next →

Filter by country